Busey Bank Sells 207 Shares of Stryker Co. (NYSE:SYK)

Busey Bank decreased its position in Stryker Co. (NYSE:SYK) by 0.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,966 shares of the medical technology company’s stock after selling 207 shares during the quarter. Busey Bank’s holdings in Stryker were worth $9,709,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Zhang Financial LLC lifted its holdings in Stryker by 55.0% during the fourth quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company’s stock worth $41,366,000 after acquiring an additional 40,784 shares during the period. Dale Q Rice Investment Management Ltd purchased a new position in shares of Stryker in the 4th quarter worth about $587,000. Berkshire Bank grew its position in Stryker by 13.8% during the fourth quarter. Berkshire Bank now owns 8,489 shares of the medical technology company’s stock valued at $3,056,000 after buying an additional 1,030 shares during the period. PFW Advisors LLC purchased a new stake in Stryker during the fourth quarter worth about $1,350,000. Finally, Traynor Capital Management Inc. bought a new stake in Stryker in the fourth quarter worth about $324,000. 77.09% of the stock is owned by institutional investors.

Stryker Stock Down 1.1 %

Shares of NYSE:SYK opened at $390.98 on Thursday. The firm has a fifty day moving average of $376.44 and a 200 day moving average of $361.98. Stryker Co. has a 52-week low of $314.05 and a 52-week high of $406.19. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The firm has a market capitalization of $149.05 billion, a PE ratio of 41.91, a price-to-earnings-growth ratio of 2.68 and a beta of 0.95.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.07% and a net margin of 16.34%. During the same quarter in the previous year, the business posted $3.46 EPS. As a group, research analysts anticipate that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be paid a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This is an increase from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a yield of 0.86%. Stryker’s payout ratio is currently 36.01%.

Insider Buying and Selling at Stryker

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the transaction, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at $36,879,954.90. The trade was a 36.43 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 5.90% of the company’s stock.

Analyst Upgrades and Downgrades

SYK has been the subject of a number of research reports. JPMorgan Chase & Co. increased their target price on shares of Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research report on Wednesday. Canaccord Genuity Group raised their target price on Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday. JMP Securities restated a “market perform” rating on shares of Stryker in a research note on Tuesday, January 7th. StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a report on Thursday. Finally, Royal Bank of Canada upped their price objective on shares of Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a report on Wednesday. Five research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $413.45.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.